NCT03016143View on ClinicalTrials.gov

Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

Allantoic Split Inactivated Seasonal flu Vaccine

Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).

BIOLOGICAL

VAXIGRIP

Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V

Trial Locations (1)

050000

Kazakh National Medical University, Almaty

All Listed Sponsors
collaborator

Asfendiyarov Kazakh National Medical University

OTHER

collaborator

Research Institute of Influenza, Russia

OTHER

lead

Research Institute for Biological Safety Problems

OTHER_GOV

NCT03016143 - Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI) | Biotech Hunter | Biotech Hunter